Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer

Version 1 : Received: 27 June 2023 / Approved: 28 June 2023 / Online: 28 June 2023 (16:02:31 CEST)

A peer-reviewed article of this Preprint also exists.

Huang, Y.; Fan, Y.; Zhao, Z.; Zhang, X.; Tucker, K.; Staley, A.; Suo, H.; Sun, W.; Shen, X.; Deng, B.; Pierce, S.R.; West, L.; Yin, Y.; Emanuele, M.J.; Zhou, C.; Bae-Jump, V. Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer. Int. J. Mol. Sci. 2023, 24, 12375. Huang, Y.; Fan, Y.; Zhao, Z.; Zhang, X.; Tucker, K.; Staley, A.; Suo, H.; Sun, W.; Shen, X.; Deng, B.; Pierce, S.R.; West, L.; Yin, Y.; Emanuele, M.J.; Zhou, C.; Bae-Jump, V. Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer. Int. J. Mol. Sci. 2023, 24, 12375.

Abstract

Ovarian cancer is the deadliest gynecological malignancy of the reproductive organs in the United States. Cyclin-dependent kinase 1 (CDK1) is an important cell cycle regulatory protein that spe-cifically controls the G2/M phase transition of the cell cycle. RO-3306 is a selective, ATP-competitive, and cell-permeable CDK1 inhibitor that shows potent anti-tumor activity in multiple pre-clinical models. In this study, we investigated the effect of CDK1 expression on the prognosis of patients with ovarian cancer and the anti-tumorigenic effect of RO-3306 in both ovarian cancer cell lines and a genetically engineered mouse model of high-grade serous ovarian cancer (KpB model). In 147 patients with epithelial ovarian cancer, overexpression of CDK1 was significantly associated with poor prognosis, compared with a low expression group. RO-3306 significantly inhibited cellular proliferation, induced apoptosis, caused cellular stress, and reduced cell migration. Treatment of KpB mice with RO-3306 for four weeks showed a significant decrease in tumor weight under obese and lean conditions without obvious side effects. Overall, our results demonstrate that inhibition of CDK1 activity by RO-3306 effectively reduces cell proliferation and tumor growth, providing biological evidence for future clinical trials of CDK1 inhibitors in ovarian cancer

Keywords

CDK1; RO-3306; ovarian cancer; apoptosis; invasion; prognosis

Subject

Medicine and Pharmacology, Obstetrics and Gynaecology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.